278 related articles for article (PubMed ID: 26503317)
1. [Variability in the clinical presentation of Pompe disease: development following enzyme replacement therapy].
Ley-Martos M; Salado-Reyes MJ; Espinosa-Rosso R; Solera-García J; Jiménez-Jiménez L
Rev Neurol; 2015 Nov; 61(9):416-20. PubMed ID: 26503317
[TBL] [Abstract][Full Text] [Related]
2. [Variability in the clinical presentation of Pompe disease in infancy: two case reports and response to treatment with human recombinant enzyme].
Moreno-Medinilla E; Berzosa-López R; Mora-Ramírez MD; Blasco-Alonso J; Martínez-Antón J
Rev Neurol; 2014 Dec; 59(11):503-7. PubMed ID: 25418145
[TBL] [Abstract][Full Text] [Related]
3. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
[TBL] [Abstract][Full Text] [Related]
4. A floppy baby.
Hebert K; Haritos D; Kannikeswaran N
Pediatr Emerg Care; 2015 Jun; 31(6):419-21. PubMed ID: 26035495
[TBL] [Abstract][Full Text] [Related]
5. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
[TBL] [Abstract][Full Text] [Related]
6. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years.
Stepien KM; Hendriksz CJ; Roberts M; Sharma R
Mol Genet Metab; 2016 Apr; 117(4):413-8. PubMed ID: 26873529
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
But WM; Lee SH; Chan AO; Lau GT
Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354
[TBL] [Abstract][Full Text] [Related]
8. Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants.
Chan MY; Jalil JA; Yakob Y; Wahab SAA; Ali EZ; Khalid MKNM; Leong HY; Chew HB; Sivabalakrishnan JB; Ngu LH
Orphanet J Rare Dis; 2023 Aug; 18(1):231. PubMed ID: 37542277
[TBL] [Abstract][Full Text] [Related]
9. Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.
Park JS; Kim HG; Shin JH; Choi YC; Kim DS
Neurol Sci; 2015 Apr; 36(4):599-605. PubMed ID: 25388776
[TBL] [Abstract][Full Text] [Related]
10. Early administration of enzyme replacement therapy for Pompe disease: short-term follow-up results.
Hamdan MA; Almalik MH; Mirghani HM
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S431-6. PubMed ID: 19067231
[TBL] [Abstract][Full Text] [Related]
11. Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings.
Teng YT; Su WJ; Hou JW; Huang SF
Chang Gung Med J; 2004 May; 27(5):379-84. PubMed ID: 15366815
[TBL] [Abstract][Full Text] [Related]
12. Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease.
Hundsberger T; Rohrbach M; Kern L; Rösler KM
J Neurol; 2013 Sep; 260(9):2279-85. PubMed ID: 23749294
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and molecular genetic study on two patients of the juvenile form of Pompe disease in China].
Qiu JJ; Wei M; Zhang WM; Shi HP
Zhonghua Er Ke Za Zhi; 2007 Oct; 45(10):760-4. PubMed ID: 18211760
[TBL] [Abstract][Full Text] [Related]
14. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
[TBL] [Abstract][Full Text] [Related]
15. Infantile-onset Pompe disease: a diagnosis not to miss.
Dixon CA; Anderson JB; Ruddy RM; Cripe LH
Pediatr Emerg Care; 2010 Apr; 26(4):293-5. PubMed ID: 20386415
[TBL] [Abstract][Full Text] [Related]
16. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
[TBL] [Abstract][Full Text] [Related]
17. [Two new mutations in the gene that codes for acid alpha-glucosidase in an adolescent with late-onset Pompe disease].
Guevara-Campos J; Romeo-Villarroel MA; González-De Guevara L; Escobar V
Rev Neurol; 2013 Sep; 57(6):265-8. PubMed ID: 24008937
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
Kishnani PS; Beckemeyer AA
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
Del Rizzo M; Fanin M; Cerutti A; Cazzorla C; Milanesi O; Nascimbeni AC; Angelini C; Giordano L; Bordugo A; Burlina AB
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S389-93. PubMed ID: 20830524
[TBL] [Abstract][Full Text] [Related]
20. Phenotype variations in early onset Pompe disease: diagnosis and treatment results with Myozyme.
Pascual SI
Adv Exp Med Biol; 2009; 652():39-46. PubMed ID: 20225018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
